Aprutumab ixadotin

Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer[1][2].

Product Specifications

CAS Number

[1708947-48-1]

Product Name Alternative

BAY 1187982

UNSPSC

12352211

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis; FGFR; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aprutumab-ixadotin.html

Purity

98.99

Solubility

10 mM in DMSO

Smiles

[Aprutumabixadotin]

References & Citations

[1]Sommer A, et al. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Cancer Res. 2016 Nov 1;76 (21) :6331-6339. |[2]Kim SB, et al. First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Target Oncol. 2019 Oct;14 (5) :591-601.